北京义翘神州

流行性感冒是一种常见的季节性可传染的呼吸道疾病,由流感病毒引起。目前,已鉴定的流感病毒有4类,包括A型,B型,C型和D型。其中,A型和B型流感病毒可引起大范围的流行性感冒,因此也更加受到生物医学界科学家们的关注。值得关注的是,以往的几次全球性流感大流行基本都是由A型流感病毒引起的,比如Hong Kong flu (1968–1969),H1N1/09 flu pandemic (2009–2010)分别由A/Hong Kong/1/1968 (H3N2)A/California/04/09 (H1N1) 导致。

接种流感疫苗是预防流行性感冒最有效的方法。每年WHO都会根据最新分离出的毒株检测数据以及上一个季节流感疫苗的性能选择3-4种不同的流感毒株作为疫苗株。近几十年,流感疫苗均为4价或者3价,可预防的流感包括1种H1N1、1种H3N2以及1种或者2种B型流感病毒(Yamagata 或/和 Victoria )。

Vaccine Strain

义翘神州ProVir病毒抗原库中覆盖了近600+流感病毒抗原,包括重组HA, NA, NP以及更多流感抗原,覆盖了近些年WHO推荐的所有流感疫苗株,可用于检测分析疫苗介导的抗体应答反应。除此之外,我们还开发了80余种流感病毒单克隆抗体试剂,可用于相关检测试剂开发。

2021-2022

A/Victoria/2570/2019 (H1N1) A/Wisconsin/588/2019 (H1N1)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40787-V08H, 40787-V08H1 HA: 40787-V08H, 40787-V08H1
NA: 40785-V08B NA: 40785-V08B
NP: 40774-V08B NP: 40774-V08B
B/Washington/02/2019 B/Phuket/3073/2013
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine
HA: 40722-V08H HA: 40498-V08B
NA: 40790-V08B NA: 40502-V07B
NP: 40755-V08B NP: 40500-V08B
A/Cambodia/E0826360/2020 (H3N2)
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40789-V08H, 40789-V08H1
NA: 40784-V08B
NP: 40778-V08B (Under Development)

2020-2021

A/Guangdong-Maonan/SWL1536/2019 (H1N1) A/Hong Kong/2671/2019 (H3N2)
Recommended for Egg-based (quadrivalent, trivalent) Vaccine Recommended for Egg-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H HA: 40721-V08H
NP: 40723-V08B NP: 40753-V08B
A/Hawaii/70/2019 (H1N1) A/Hong Kong/45/2019 (H3N2)
Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine Recommended for Cell- or recombinant-based (quadrivalent, trivalent) Vaccine
HA: 40717-V08H HA: 40765-V08H (Under Development)
NP: 40724-V08B NP: 40754-V08B
B/Phuket/3073/2013 B/Washington/02/2019
Recommended for Egg-based, Cell- or recombinant-based (quadrivalent) Vaccine Recommended for Egg-based, Cell- or recombinant-base (quadrivalent, trivalent) Vaccine
HA: 40498-V08B HA: 40722-V08H
NA: 40502-V07B NP: 40755-V08B
NP: 40500-V08B  

2019-2020

A/Brisbane/02/2018 (H1N1) A/Kansas/14/2017 (H3N2)
Recommended for Egg-based(quadrivalent) Vaccine Recommended for Egg-based(quadrivalent) Vaccine
HA: 40719-V08H HA: 40720-V08H
NP: 40776-V08B NP: 40779-V08B
B/Phuket/3073/2013 B/Colorado/06/2017
Recommended for Egg-based(quadrivalent) Vaccine Recommended for Egg-based(quadrivalent); trivalent Vaccine
HA: 40498-V08B HA: 40581-V08H
NA: 40502-V07B NP: 40782-V08B (Under Development)
NP: 40500-V08B  

2018-2019

A/Michigan/45/2015 (H1N1) A/Singapore/INFIMH-16-0019/2016 (H3N2)
Recommended for quadrivalent Vaccine Recommended for quadrivalent Vaccine
HA: 40567-V08H1 HA: 40580-V08H
NA: 40568-V08B NP: 40779-V08B (Under Development)
NP: 40777-V08B (Under Development)  
B/Phuket/3073/2013 B/Colorado/06/2017
Recommended for quadrivalent Vaccine Recommended for quadrivalent; trivalent Vaccine
HA: 40498-V08B HA: 40581-V08H
NA: 40502-V07B NP: 40782-V08B (Under Development)
NP: 40500-V08B  

2017-2018

A/Michigan/45/2015 (H1N1) A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: 40567-V08H1 HA: 40555-V08B
NA: 40568-V08B NA: 40569-V08B
NP: 40777-V08B NP: 40781-V08B
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for trivalent Vaccine Recommended for quadrivalent Vaccine
HA: 40016-V08B HA: 40498-V08B
NA: 40203-VNAHC NA: 40502-V07B
NP: 40783-V08B (Under Development) NP: 40500-V08B

2016-2017

A/California/7/2009 (H1N1) A/Hong Kong/4801/2014 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: 11085-V08B HA: 40555-V08B
NP: 40205-V08B NA: 40569-V08B
  NP: 40781-V08B
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for trivalent Vaccine Recommended for quadrivalent Vaccine
HA: 40016-V08B HA: 40498-V08B
NA: 40203-VNAHC NA: 40502-V07B
NP: 40783-V08B (Under Development) NP: 40500-V08B

2015-2016

A/California/7/2009 (H1N1) A/Switzerland/9715293/2013 (H3N2)
Recommended for trivalent Vaccine Recommended for trivalent Vaccine
HA: 11085-V08B HA: 40497-V08B
NP: 40205-V08B NA: 40499-V08B
B/Brisbane/60/2008 B/Phuket/3073/2013
Recommended for quadrivalent Vaccine Recommended for trivalent Vaccine
HA: 40016-V08B HA: 40498-V08B
NA: 40203-VNAHC NA: 40502-V07B
NP: 40783-V08B (Under Development) NP: 40500-V08B
请从上面促销列表中查询所需产品,并联系我们:
北京义翘神州科技股份有限公司

电话:400-890-9989
邮箱:marketing@sinobiological.cn
官网:cn.sinobiological.com
地址:北京市北京经济技术开发区科创十街18号院9号楼

北京义翘神州
关注"北京义翘神州"
获取更多资讯与促销信息
本网页由义翘神州委托 生物通 制作
北京义翘神州科技股份有限公司拥有以上广告资料(包括但不限于图片和文字)的版权